found that high CDK1 expression drives the progression of adrenocortical carcinoma by regulating the G2/M phase transition.[56] Over the past few decades, a variety of selective inhibitors and pan‐inhibitors targeting CDK1 have been developed. This evidence concerns the gene CDK1 and adrenal cortex carcinoma.